Predicting the future of human gene therapy for cardiovascular diseases: What will the management of coronary artery disease be like in 2005 and 2010?

American Journal of Cardiology

Volumn 92, Issue 9 SUPPL. 2, 2003, Pages 32-35

  Dzau, Victor J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CYCLIN DEPENDENT KINASE; HEME OXYGENASE; NITRIC OXIDE SYNTHASE; RECOMBINANT DNA; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT PROTEIN; RECOMBINANT VASCULOTROPIN; RETINOBLASTOMA PROTEIN; SYNTHETIC DNA; TRANSCRIPTION FACTOR E2F;

ADOPTIVE IMMUNOTHERAPY; ANGIOGENESIS; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL CYCLE; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG TARGETING; GENE THERAPY; GENETIC TRANSFECTION; GRAFT FAILURE; HEART INFARCTION SIZE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HEMATOPOIETIC STEM CELL; HIGH RISK POPULATION; HUMAN; IMMUNOCYTOTOXICITY; INFLAMMATION; MITOSIS INHIBITION; MUSCLE REGENERATION; NONHUMAN; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RESTENOSIS; RISK MANAGEMENT; TISSUE REPAIR;

EID: 0242627525     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00966-4     Document Type: Conference Paper

References (14)

1. Ylä-Herttuala S., Martin J.F. Cardiovascular gene therapy. Lancet. 355:2000;213-222.
2. Grossman M., Rader D.J., Muller D.W., Kolansky D.M., Kozarsky K., Clark B.J., Stein E.A., Lupien P.J., Brewer H.B., Raper S.E. A pilot study of ex vivo gene therapy for homozygous familiar hypercholesterolemia. Nat Med. 1:1995;1148-1154.
3. Rasmussen H.S., Rasmussen C.S., Macko J., Yonehiro G. Angiogenic gene therapy strategies for the treatment of cardiovascular disease. Curr Opin Mol Ther. 4:2002;476-481.
4. Rissanen T.T., Vajanto I., Ylä-Herttuala S. Gene therapy for therapeutic angiogenesis in critically ischaemic lower limb - on the way to the clinic. Eur J Clin Invest. 31:2001;651-666.
5. Muhs A., Heublein B., Schletter J., Herrmann A., Rudiger M., Sturn M., Grust A., Malms J., Schrader J., von der Leyen H.E. Preclinical evaluation of inducible nitric oxide synthase lipoplex gene therapy for inhibition of stent-induced vascular neointimal lesion formation. Hum Gene Ther. 14:2003;375-383.
6. Dzau V.J., Braun-Dullaeus R.C., Sedding D.G. Vascular proliferation and atherosclerosis new perspectives and therapeutic strategies . Nat Med. 8:2002;1249-1256.
7. Morishita R., Gibbons G.H., Horiuchi M., Ellison K.E., Nakama M., Zhang L., Kareda Y., Ogihara T., Dzau V.J. A gene therapy strategy using a transcription factor decoy of the EZF binding site inhibits smooth muscle cell proliferation in vivo. Proc Natl Acad Sci U S A. 92:1995;5855-5859.
8. Bourassa M.G. Long-term vein graft patency. Curr Opin Cardiol. 9:1994;685-691.
9. Mann M.J., Whittemore A.D., Donaldson M.C., Belkin M., Conte M.S., Polak J.F., Orav E.J., Ehsan A., Dell'Acqua G., Dzau V.J. Ex-vivo gene therapy of human vascular bypass grafts with EF2 decoy the PREVENT single-centre, randomised, controlled trial . Lancet. 354:1999;1493-1498.
10. Pachori A.S. Long term cardiac and extracardiac gene expression following recombinant AAV-2 mediated intramyocardial gene delivery. Mol Ther. 7:(suppl 1):2003;359.
11. Melo L.G., Agrawal R., Zhang L., Rezvani M., Mangi A.A., Ehsan A., Griese D.P., Dell'Acqua G., Mann M.J., Oyama J., et al. Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. Circulation. 105:2002;602-607.
12. Abunasra H.J., Smolenski R.T., Morrison K., Yap J., Sheppard M.N., O'Brien T., Suzuki K., Jayakumar J., Yacoub M.H. Efficacy of adenoviral gene transfer with manganese superoxide dismutase and endothelial nitric oxide synthase in reducing ischemia and reperfusion injury. Eur J Cardiothorac Surg. 20:2001;153-158.
13. Asahara T., Masuda H., Takahashi T., Kalka C., Pastore C., Silver M., Kearne M., Magner M., Isner J.M. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 85:1999;221-228.
14. Orlic D., Kajstura J., Chimenti S., Jakoniuk I., Anderson S.M., Li B., Pickel J., McKay R., Nadal-Ginard B., Bodine D.M., Leri A., Anversa P. Bone marrow cells regenerate infarcted myocardium. Nature. 410:2001;701-705.